ADmit THERAPEUTICS - test for an early AD detection. Alzheimer's disease
test for an early AD detectionAlzheimer's disease
test for an early AD detectionAlzheimer's disease  

DIAGNOSTIC

Our diagnostic test represents the determination of biomarkers non-related with β-amyloid nor tau. Therefore, our unique value proposition is that our test is based on an epigenetic analysis in blood samples, covering the analysis of a large number of methylcytosines in mtDNA by next generation sequencing. As systemic mitochondrial dysfunction has been proposed just before the appearance of cerebral abnormal protein aggregates, our findings may become a pool of biomarkers very useful for the detection of patients at early stages of AD.

PIPELINE

It is envisioned that ADmit Therapeutics will develop a new laboratory-based IVD device, obtaining the corresponding CE mark in 2023.
This website uses our own cookies and third-party cookies to collect information, in order to improve our services. Your continued use of this website constitutes acceptance of the installation of these cookies. The user has the option of configuring their browser in order to prevent cookies from being installed on their hard drive, although they must keep in mind that doing so may cause difficulties in their use of the webpage. I Agree  How to configure browser